Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data

One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug. The post Axsome Aims…

Read More

Vaccines Jettisoned by CDC Safeguarded Millions From Disease

The federal government scaled back its recommended childhood vaccines, sidelining six that have safeguarded millions from serious diseases, long-term disability, and death.  Just three of those that the Centers for Disease Control and Prevention says it will no longer routinely recommend — against hepatitis A, hepatitis B, and rotavirus — have prevented nearly 2 million hospitalizations and 90,000 deaths in the…

Read More

The Missing Piece: Tech and Mental Health

By involving highly experienced therapists and mental health administration experts from the beginning of development of new tech, we not only build tools that are more effective, but also build trust and confidence among clinicians. The post The Missing Piece: Tech and Mental Health appeared first on MedCity News.

Read More